Amphastar Pharmaceuticals, Inc.
AMPH · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $732 | $644 | $499 | $438 |
| % Growth | 13.6% | 29.1% | 14% | – |
| Cost of Goods Sold | $358 | $293 | $250 | $238 |
| Gross Profit | $374 | $351 | $249 | $200 |
| % Margin | 51.1% | 54.5% | 49.9% | 45.6% |
| R&D Expenses | $74 | $74 | $75 | $61 |
| G&A Expenses | $57 | $52 | $45 | $51 |
| SG&A Expenses | $95 | $80 | $67 | $69 |
| Sales & Mktg Exp. | $38 | $29 | $22 | $17 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $168 | $154 | $141 | $130 |
| Operating Income | $205 | $197 | $107 | $70 |
| % Margin | 28.1% | 30.6% | 21.5% | 16% |
| Other Income/Exp. Net | -$16 | -$28 | $7 | $14 |
| Pre-Tax Income | $189 | $169 | $115 | $84 |
| Tax Expense | $30 | $32 | $23 | $21 |
| Net Income | $160 | $138 | $91 | $62 |
| % Margin | 21.8% | 21.3% | 18.3% | 14.2% |
| EPS | 3.29 | 2.85 | 1.88 | 1.3 |
| % Growth | 15.4% | 51.6% | 44.6% | – |
| EPS Diluted | 3.06 | 2.6 | 1.74 | 1.25 |
| Weighted Avg Shares Out | 48 | 48 | 49 | 48 |
| Weighted Avg Shares Out Dil | 52 | 53 | 52 | 50 |
| Supplemental Information | – | – | – | – |
| Interest Income | $11 | $5 | $1 | $1 |
| Interest Expense | $30 | $27 | $2 | $1 |
| Depreciation & Amortization | $57 | $42 | $28 | $27 |
| EBITDA | $277 | $240 | $146 | $112 |
| % Margin | 37.9% | 37.3% | 29.3% | 25.5% |